Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
J Hematol Oncol. 2017 Sep 20;10(1):155. doi: 10.1186/s13045-017-0522-z.
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and more attention as a novel strategy of antitumor immunotherapy. BsAb not only offers an effective linkage between therapeutics (e.g., immune effector cells, radionuclides) and targets (e.g., tumor cells) but also simultaneously blocks two different oncogenic mediators. In recent decades, a variety of BsAb formats have been generated. According to the structure of Fc domain, BsAb can be classified into two types: IgG-like format and Fc-free format. Among these formats, bispecific T cell engagers (BiTEs) and triomabs are commonly investigated. BsAb has achieved an exciting breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials. In this review, we focus on the preclinical experiments and clinical studies of epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor (HER) family, carcinoembryonic antigen (CEA), and prostate-specific membrane antigen (PSMA) related BsAbs in solid tumors, as well as discuss the challenges and corresponding approaches in clinical application.
癌症免疫疗法是癌症治疗中最令人兴奋的进展。与免疫检查点阻断和嵌合抗原受体 T 细胞（CAR-T）类似，双特异性抗体（BsAb）作为一种新型抗肿瘤免疫疗法策略，越来越受到关注。BsAb 不仅提供了治疗剂（如免疫效应细胞、放射性核素）和靶标（如肿瘤细胞）之间的有效连接，而且还同时阻断了两种不同的致癌介质。在最近几十年中，已经产生了多种 BsAb 形式。根据 Fc 结构域的结构，BsAb 可分为两类：IgG 样结构和无 Fc 结构。在这些结构中，双特异性 T 细胞衔接器（BiTEs）和三联抗体是常用的研究对象。BsAb 在血液恶性肿瘤中取得了令人兴奋的突破，并在各种临床试验中在实体瘤中显示出有希望的结果。在这篇综述中，我们重点介绍了与实体瘤中上皮细胞黏附分子（EpCAM）、人表皮生长因子受体（HER）家族、癌胚抗原（CEA）和前列腺特异性膜抗原（PSMA）相关的 BsAb 的临床前实验和临床研究，并讨论了临床应用中的挑战和相应方法。
